Logo Image
News|Articles|December 28, 2007

FDA Panel Rejects OTC Status for Merck’s “Mevacor”

The US Food and Drug Administration's joint panel of the Nonprescription Drugs Advisory Committee and the Endocrinologic and Metabolic Drugs Advisory Committee voted against recommending approval of the over-the-counter use of Merck & Co.'s “Mevacor” (lovastatin) 20 mg.

Whitehouse Station, NJ (Dec. 13)-The US Food and Drug Administration’s joint panel of the Nonprescription Drugs Advisory Committee and the Endocrinologic and Metabolic Drugs Advisory Committee voted against recommending approval of the over-the-counter (OTC) use of Merck & Co.’s “Mevacor” (lovastatin) 20 mg. The drug is designed to help lower LDL cholesterol, which may prevent a first heart attack.

“We are disappointed in today’s outcome,” said Edwin L. Hemwall, vice-president of global OTC regulatory and scientific affairs at Merck, in a company release. “We felt we presented a compelling case to the committee that nonprescription Mevacor 20 mg would be a valuable option for motivated consumers who know they have moderately elevated cholesterol and certain risk factors and are already talking with their healthcare provider.”

Although FDA is not bound by the committee’s recommendation, the agency takes its advice into consideration. FDA is expected to take action by Jan. 26, 2008, according to Merck.

 

Related to this article

View more
Quality inspector walking through processing area with stainless tanks and tablet | Image Credit: ©Surachai -stock.adobe.com
Successful Internal Audit Planning and Execution
At the PDA/FDA Joint Regulatory Conference 2026, Helen Motamen, MS global head, Sanofi Quality Audit, Inspection, Intelligence & Advocacy, at Sanofi, provided advice for creating a strong internal audit program.
Read more
Intravenous therapy; drip chamber in focus against a colorful background | Image Credit: ©Anna Jurkovska -stock.adobe.com
Assessment of Silicone Oil Cleaning on Indirect Surfaces in Aseptic Manufacturing
This article explores the historical use of silicone oil in the performance of primary drug product packaging; design of experiment test results for selection of the cleaning agent and CCPs; assessment of visible residue limits and Fourier-transform infrared spectroscopy surface analysis; and setting health-based exposure limits for silicone oil using a non-uniform distribution model, and a previously published permitted daily exposure.
Read more